Topline results from phase 2b clinical trial of UBX1325 for DME expected in Q1 2025
This phase 2b study (ASPIRE) is currently underway.
(Image credit: AdobeStock/J Bettencourt/peopleimages.com)
UNITY believes that its lead candidate, UBX1325 (foselutoclax), with its unique mechanism of action, has the potential to improve long-term visual outcomes in DME patients by addressing treatment burdens and suboptimal responses seen with standard therapies.1
A phase 2b trial, dubbed ASPIRE, evaluating the safety and efficacy of UBX1325 compared to aflibercept is underway. Topline results from the 24-week primary endpoint data are expected in the first quarter of 2025, with 36-week data following in the second quarter of 2025. The study's endpoint for regulatory approval will assess best-corrected visual acuity (BCVA) using the ETDRS scale, a tool for assessing visual acuity measurements.Data from the ASPIRE study is expected to provide essential insights to inform the design of potential pivotal trials. 1
UNITY had a Type C interaction with the U.S. Food and Drug Administration (FDA) regarding the development of UBX1325. Based on this feedback, the company anticipates that a pivotal study would need to be a non-inferiority trial comparing UBX1325 to aflibercept.1
